Evidence map›Paper›PMID 30902482›Full record

SynthesisVaccine2019

A systematic review of vaccine preventable disease surveillance cost studies.

Ngozi Adaeze Erondu, Lisa Ferland, Betiel Hadgu Haile, Taiwo Abimbola

Open access · greenAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Vaccine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Ngozi Adaeze EronduLondon School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, United Kingdom; The Global Bridge Group, LLC, Pleasanton, CA, USA. Electronic address: ghconsulting@ngozierondu.com.
Lisa FerlandThe Global Bridge Group, LLC, Pleasanton, CA, USA.
Betiel Hadgu HaileThe Global Bridge Group, LLC, Pleasanton, CA, USA.
Taiwo AbimbolaU.S. Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: iip2@cdc.gov.
Centers for Disease Control and Prevention · USUniversity of London · GB

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

backgroundPlanning and monitoring vaccine introduction and effectiveness relies on strong vaccine-preventable disease (VPD) surveillance. In low and middle-income countries (LMICs) especially, cost is a commonly reported barrier to VPD surveillance system maintenance and performance; however, it is rarely calculated or assessed. This review describes and compares studies on the availability of cost information for VPD surveillance systems in LMICs to facilitate the design of future cost studies of VPD surveillance.

methodsPubMed, Web of Science, and EconLit were used to identify peer-reviewed articles and Google was searched for relevant grey literature. Studies selected described characteristics and results of VPD surveillance systems cost studies performed in LMICs. Studies were categorized according to the type of VPD surveillance system, study aim, the annual cost of the system, and per capita costs.

resultsEleven studies were identified that assessed the cost of VPD surveillance systems. The studies assessed systems from six low-income countries, two low-middle-income countries, and three middle-income countries. The majority of the studies (n = 7) were conducted in sub-Saharan Africa and fifteen distinct VPD surveillance systems were assessed across the studies. Most studies aimed to estimate incremental costs of additional surveillance components and presented VPD surveillance system costs as mean annual costs per resource category, health structure level, and by VPD surveillance activity. Staff time/personnel cost represents the largest cost driver, ranging from 21% to 61% of total VPD surveillance system costs across nine studies identifying a cost driver.

conclusionsThis review provides a starting point to guide LMICs to invest and advocate for more robust VPD surveillance systems. Critical gaps were identified including limited information on the cost of laboratory surveillance, challenges with costing shared resources, and missing data on capital costs. Appropriate guidance is needed to guide LMICs conducting studies on VPD surveillance system costs.

Indexed as

Costs and Cost AnalysisCost-Benefit AnalysisDeveloping CountriesHealth Care CostsHealth ResourcesHumansPublic Health SurveillanceVaccinationVaccine-Preventable DiseasesVaccinesVaccinesCost analysisLow incomeMiddle incomePublic health surveillanceSystematic reviewVaccine preventable diseases

Identifiers

PMID30902482
PMCPMC6501781
OpenAlexW2923873901

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.